title: Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer.
abstract: Taxane therapy is commonly used in the treatment of metastatic breast cancer. However, most patients will eventually become refractory to these agents. Ixabepilone is a newly approved chemotherapeutic agent for the treatment of metastatic breast cancer. Although it targets microtubules similarly to docetaxel and paclitaxel, ixabepilone has activity in patients that are refractory to taxanes. This review summarizes the pharmacology of ixapebilone and clinical trials with the drug both as a single agent and in combination. Data were obtained using searches of PubMed and abstracts of the annual meetings of the American Society of Clinical Oncology and the San Antonio Breast Cancer Symposium from 1995 to 2008. Ixapebilone is a semi-synthetic analog of epothilone B that acts to induce apoptosis of cancer cells via the stabilization of microtubules. Phase I clinical trials have employed various dosing schedules ranging from daily to weekly to 3-weekly. Dose-limiting toxicites included neuropathy and neutropenia. Responses were seen in a variety of tumor types. Phase II studies verified activity in taxane-refractory metastatic breast cancer. The FDA has approved ixabepilone for use as monotherapy and in combination with capecitabine for the treatment of metastatic breast cancer. Ixabepilone is an efficacious option for patients with refractory metastatic breast cancer. The safety profile is similar to that of taxanes, with neuropathy and neutropenia being dose-limiting. Studies are ongoing with the use of both iv and oral formulations and in combination with other chemotherapeutic and biologic agents.
authors.affiliation: UPMC Magee-Womens Cancer, Program, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
authors.forename: Shannon
authors.initials: S
authors.lastname: Puhalla
authors.forename: Adam
authors.initials: A
authors.lastname: Brufsky
references.citation: Ann Oncol. 2007 Jul;18 Suppl 5:v9-15
references.pmid: 17656562
references.citation: J Clin Oncol. 2007 Aug 10;25(23):3407-14
references.pmid: 17606974
references.citation: Clin Cancer Res. 2005 Sep 1;11(17):6233-9
references.pmid: 16144926
references.citation: J Clin Oncol. 2006 May 1;24(13):2084-91
references.pmid: 16648510
references.citation: J Clin Oncol. 2001 Feb 15;19(4):1195-206
references.pmid: 11181686
references.citation: N Engl J Med. 2007 Dec 27;357(26):2666-76
references.pmid: 18160686
references.citation: Clin Cancer Res. 2004 Feb 15;10(4):1289-98
references.pmid: 14977827
references.citation: Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2904-9
references.pmid: 10688884
references.citation: Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4256-61
references.pmid: 10200249
references.citation: Clin Cancer Res. 2002 Jul;8(7):2035-43
references.pmid: 12114401
references.citation: Invest New Drugs. 2006 Sep;24(5):441-6
references.pmid: 16586011
references.citation: J Clin Oncol. 2007 Nov 20;25(33):5210-7
references.pmid: 17968020
references.citation: J Clin Oncol. 2009 Feb 1;27(4):526-34
references.pmid: 19075286
references.citation: Cancer. 2007 Aug 1;110(3):556-63
references.pmid: 17577218
references.citation: Nature. 1995 Jun 1;375(6530):424-7
references.pmid: 7760939
references.citation: J Clin Oncol. 2005 Mar 1;23(7):1439-46
references.pmid: 15735119
references.citation: Ann Oncol. 2004 Jun;15(6):928-32
references.pmid: 15151950
references.citation: J Clin Oncol. 2008 Apr 10;26(11):1810-6
references.pmid: 18347007
references.citation: J Clin Oncol. 2005 Dec 1;23(34):8724-9
references.pmid: 16314632
references.citation: J Clin Oncol. 2007 Aug 10;25(23):3421-7
references.pmid: 17606971
references.citation: J Clin Oncol. 2005 Nov 1;23(31):7794-803
references.pmid: 16172456
references.citation: J Clin Oncol. 2005 May 1;23(13):3069-73
references.pmid: 15860865
references.citation: J Clin Oncol. 2007 Aug 10;25(23):3448-55
references.pmid: 17606973
references.citation: Cancer. 2013 May 1;119(9):1683-9
references.pmid: 23310949
references.citation: Drug Discov Today. 2001 Nov 15;6(22):1153-1164
references.pmid: 11700217
references.citation: J Clin Oncol. 2007 Aug 10;25(23):3415-20
references.pmid: 17606972
references.citation: N Engl J Med. 2008 Apr 17;358(16):1663-71
references.pmid: 18420499
references.citation: Biochemistry. 2002 Mar 26;41(12):3870-4
references.pmid: 11900528
references.citation: J Clin Oncol. 2003 May 1;21(9):1866-73
references.pmid: 12721265
references.citation: J Clin Oncol. 2005 Apr 20;23(12):2726-34
references.pmid: 15837987
references.citation: J Antibiot (Tokyo). 1996 Jun;49(6):560-3
references.pmid: 8698639
references.citation: Cancer Res. 2001 Apr 15;61(8):3369-72
references.pmid: 11309294
references.citation: Cancer Res. 1995 Jun 1;55(11):2325-33
references.pmid: 7757983
references.citation: Mol Cancer Ther. 2001 Nov;1(1):3-10
references.pmid: 12467233
references.citation: Ann Oncol. 2007 Jan;18(1):190-195
references.pmid: 17018704
references.citation: J Clin Oncol. 2007 Mar 20;25(9):1082-8
references.pmid: 17261851
references.citation: Invest New Drugs. 2007 Feb;25(1):63-7
references.pmid: 16933153
references.citation: Cancer Chemother Pharmacol. 2008 Apr;61(5):751-8
references.pmid: 17594093
references.citation: Invest New Drugs. 2006 Nov;24(6):515-20
references.pmid: 16699973
references.citation: Cancer. 2005 May 1;103(9):1932-8
references.pmid: 15800893
references.citation: J Clin Oncol. 2008 Apr 1;26(10):1642-9
references.pmid: 18375893
references.citation: Clin Cancer Res. 2001 May;7(5):1429-37
references.pmid: 11350914
references.citation: Nat Rev Cancer. 2004 Apr;4(4):253-65
references.pmid: 15057285
references.citation: Invest New Drugs. 2007 Aug;25(4):335-41
references.pmid: 17364235
references.citation: J Clin Oncol. 2007 Aug 10;25(23):3399-406
references.pmid: 17606975